a cure for hep c, aids, the flu and dengue..., page-125

G'day Bumblingninny,

I'd say it's highly unlikely that the entire cache have finished dosing.

A number of patients have finished, and although these results cannot necessarily be extrapolated across to the remaining patients yet to complete or commence dosing, it is, as you state, a significant reduction in risk. This trial could easily still be halted if negative safety outcomes are encountered, but that risk, though real, is diminishing daily.

It seems we can infer from silence the continuing delays at the Argentinian site. This second site acts as a circumstantial and genetic hedge against the outcomes at the Thai site - this benefit must be weighed against the need to expedite the trial completion. Trying to take the most objective view (not that it necessarily aligns with my impatient nature!), you do have to credit management for not rushing through the procedure to the detriment of of the risk-management protocols.

I'd still put this in the highest risk category on the ASX, though the distinction seems a bit arbitrary when you look at some of the other all-or-nothing stocks out there (those involved in Artemis #1 would know all about it). BIT225 is a first-in-class drug with known efficacy and a high degree of synergism with the current standard of care and the emerging protease-inhibitors. At these now greatly increased doses, demonstrating safety and tolerability has always been the major outcome for my investment - demonstrate a full completion rate and more than half the risk is accounted for as far as I'm concerned. Phase III is where the dosage can be optimised, a view I suspect the potential partners would share.

Cheers

Tawny